Chronic and acute liver diseases remain among the most undertreated conditions in modern medicine, partly because the inflammatory cascades that drive hepatic damage have been poorly understood at the molecular level. A growing body of evidence now places neutrophil extracellular traps — web-like chromatin and protein structures released by dying neutrophils — at the center of liver pathology, suggesting that targeting this mechanism could open a fundamentally new therapeutic avenue.
This review in Acta Pharmacologica Sinica synthesizes current understanding of how NETs contribute to a spectrum of liver diseases, encompassing non-alcoholic fatty liver disease, alcoholic liver disease, viral hepatitis-related injury, ischemia-reperfusion injury, and acute liver failure. NETs are formed through a regulated cell-death process called NETosis, which can be triggered by pathogen-associated molecular patterns, sterile inflammation, or metabolic stress. Once deployed, these structures activate hepatic stellate cells, promote coagulation cascades, amplify inflammasome activity, and sustain a feed-forward loop of sterile inflammation — all of which accelerate fibrosis and organ failure. The review maps specific molecular mediators, including PAD4 (the enzyme that citrullinates histones during NETosis), NADPH oxidase, and TLR4 signaling, as candidate intervention points.
From a broader research perspective, the NET field in liver disease is still maturing. Most mechanistic evidence derives from murine models, and human studies linking NET biomarkers to clinical outcomes remain relatively small. Nevertheless, PAD4 inhibitors, DNase I-based therapies to dissolve NET scaffolds, and anti-citrullinated histone antibodies are already being investigated in adjacent inflammatory diseases, lending translational credibility to the hepatic applications discussed here. This is an incrementally significant review rather than a paradigm-shifting discovery — but it usefully consolidates a fragmented literature and may accelerate drug-development timelines by clarifying which molecular nodes are most tractable. For adults concerned about liver health, the findings reinforce that systemic inflammation and innate immune dysregulation, not just dietary fat accumulation, are central drivers of liver disease progression.